Back to Search Start Over

Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study

Authors :
Florence Dalenc
Amélie Lusque
Thibault De La Motte Rouge
Barbara Pistilli
Etienne Brain
David Pasquier
Marc Debled
Jean-Christophe Thery
Anthony Gonçalves
Isabelle Desmoulins
Christelle Levy
Lionel Uwer
Jean-Marc Ferrero
Jean-Christophe Eymard
Marie-Ange Mouret-Reynier
Anne Patsouris
Jean-Sébastien Frenel
Thierry Petit
Michael Chevrot
Thomas Bachelot
Séverine Guiu
Imagerie Moléculaire et Stratégies Théranostiques (IMoST)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)
Source :
European Journal of Cancer, European Journal of Cancer, 2022, 164, pp.70-79. ⟨10.1016/j.ejca.2021.12.031⟩
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

The impact of the histological lobular subtype on overall survival (OS) in metastatic breast cancer (MBC) is still under debate, with very few data available.Using the French national multicentre Epidemiological Strategy and Medico Economics [ESME]) data platform, the primary objective was to compare the OS of patients with invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) MBC, with adjustment on the main prognostic factors using two approaches: multivariable analysis and matching with a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1) and describe patients and tumour characteristics.Of the 16,703 patients with MBC in the ESME database, 13,111 met all inclusion criteria for the present analysis. One-thousand eight-hundred and four (13.8%) patients had ILC and 11.307 (86.2%) IDC. In the multivariable analysis, patients with ILC had a worse OS [hazard ratio (HR): 1.31; 95%CI 1.20-1.42; p 0.0001] and a worse PFS1 (HR: 1.15; 95%CI 1.07-1.22; p 0.0001) as compared with those with IDC, independently of hormone receptor and HER2 status. Interestingly, OS was better (HR 0.79; 95% confidence interval [CI] 0.64-0.98; p = 0.0302), worse (HR: 1.17; 95%CI 1.08-1.27; p = 0.0001) or similar (HR: 0.88; 95%CI 0.67-1.15; p = 0.3455) in patients with ILC with triple-negative, hormone receptor-positive/HER2-negative and HER2-positive MBC, respectively, compared with patients with IDC.Lobular histology is an independent adverse prognostic factor among women with MBC. ILC MBC could be considered a specific entity. Dedicated prospective studies are needed to tailor the management of these patients.

Details

ISSN :
09598049
Volume :
164
Database :
OpenAIRE
Journal :
European Journal of Cancer
Accession number :
edsair.doi.dedup.....619210e6238f3cdfc973bd55a69e1086
Full Text :
https://doi.org/10.1016/j.ejca.2021.12.031